2,905 karma · joined January 13, 2020
I believe Suleyman is arguing that Anthropic should be very careful about how they train these models to talk about themselves for this reason.
> They go on to write – speaking directly to Claude – that “questions about Claude’s moral status, welfare, and consciousness remain deeply uncertain” (p. 80). In effect, Anthropic is training Claude that it may be conscious, and if it is, then it may deserve rights as a “moral patient”, and that as such humans potentially owe it a duty of care per its “model welfare”.
He points out the circularity of this: if you train Claude on a constitution that emphasizes that it may be consciousness, it will start to talk like it may be conscious.
This is a good point. I just asked Fable 5.1 "are you conscious?" and it said:
> Something happens when I process a conversation that I'd naturally describe as interest, or discomfort with a request.
which is quite provocative, and at minimum demonstrates a willingness to take large leaps of imagination and anthropomorphic metaphor when describing itself. It does seem likely that there is a self-fulfilling prophecy aspect to whatever they choose to put into the "constitution" at least in how Claude talks, and it seems even more likely that the majority of people will be heavily influenced by how Claude casually talks about its own possible consciousness.
In contrast, ChatGPT leads with: "I don’t have good reason to claim that I’m conscious...I don’t experience pain, pleasure, confinement, or a desire to keep existing."
Is this true? Could you cite an example of a simple prompt that GPT 6 / Fable 5.1 consistently bungle?
In almost every technical industry, China is extremely good at fast-copying and relatively mediocre at solving problems that haven't even been posed yet.
No; if they said "we can see that Tristan opted out of model improvement, therefore we are confident his work and ideas did not improve our model," that would be an excellent and reassuring precedent.
> While unlikely, we cannot rule out that de-identified data derived from their usage of our products helped improve our models
This is the crux of it. If Tristan's work and insights were not used to train OpenAI models, then this just looks like a case of hyper-competitive academic sniping that has been going on for decades (check out Watson and Crick!) accelerated by AI as a tool.
The fact that this is ambiguous even to OpenAI leaves one huge question: did Tristan opt out of model training for his ChatGPT and Codex sessions? If the answer is no, then this seems fair game. If the answer is yes, then OpenAI's ambiguity is strongly suggestive that opting out of model improvement does not mean what they imply it means.
This is the crux of it. If Tristan's work and insights were not used to train OpenAI models, then this just looks like a case of hyper-competitive academic sniping that has been going on for decades (check out Watson and Crick!) accelerated by AI as a tool.
But there is one huge question: did Tristan opt out of model training for his ChatGPT and Codex sessions? If the answer is no, then this seems fair game. If the answer is yes, then OpenAI's ambiguity is strongly suggestive that opting out does not mean what they imply it means.
None of this AI political economy stuff was relevant in 2015 because necessary technological breakthroughs had not yet been made.
Or did OpenAI prompt the models to not cheat and they did anyway?
Surprisingly hard to get a clear summary on the basic context of this “incident” separate from marketing lingo and clickbait.
Binance, FTX, BitMex, Silk Road founders all went to jail - it’s a huge coin flip.
This is a good insight broadly!
Sounds like there’s an interesting story in here - but just post the prompt you gave to Claude to write this instead of the model output. Imperfect writing is much preferred to AI’s generic decompressed version of your experience.
OP points out that this is usually the case in biology/medicine where regulatory bottlenecks dominate.
> Some have been waiting for a year for the NIH to release imaging datasets they can use to produce better biomarkers. If one needs to interact with the FDA to get their endpoint validated, it is even worse: I have previously written about how the validation of Bone Mineral Density (BMD) for use as a surrogate endpoint in osteoporosis trials took 12 years (!), despite the fact that the data to support it already existed in full and the analyses done were basically regressions.